US2019033290A1PendingUtilityA1
Diagnosis and treatment of invasive aspergillosis
Assignee: BRIGHAM & WOMENS HOSPITAL INCPriority: Sep 7, 2012Filed: Jun 26, 2018Published: Jan 31, 2019
Est. expirySep 7, 2032(~6.1 yrs left)· nominal 20-yr term from priority
Inventors:Sophia KooHoratio R. ThomasJames ComolliPreshious ReardenLindsey R. BadenFrancisco M. Marty
G01N 2333/38A61P 31/10G01N 33/56961C12Q 1/04G01N 2800/52A61K 31/496A61K 31/513G01N 2500/10G01N 33/497A61K 31/427A61K 38/12A61K 31/7048C12Q 1/025G01N 2033/4977G01N 33/4977
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods for diagnosing, treating, and monitoring the treatment of invasive aspergillosis (IA) are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having IA.
Claims
exact text as granted — not AI-modified1 - 4 . (canceled)
5 . A method of detecting the presence of an Aspergillus fumigatus, A. terreus, or A. calidoustus infection in a subject, the method comprising:
obtaining a sample comprising breath of a subject, or headspace from a culture suspected of comprising Aspergillus isolated from a subject; determining the presence of one, two, three, or more Volatile Organic Compounds (VOCs) selected from the group consisting of camphene, alpha-pinene, beta-pinene, limonene, alpha-bergamotene, alpha-santalene, beta-elemene, acoradien, chamigrene, 1,5,9-trimethyl cyclododecatriene, 9-decene-2-one and beta-sesquiphellandrene in the sample, wherein:
the presence of one, two, three, or more of camphene, alpha-pinene, beta-pinene, limonene, or alpha-bergamotene indicates the presence of an A. fumigatus infection;
the presence of one, two, three, or more of alpha-santalene, beta-elemene, acoradien, chamigrene, and 1,5,9-trimethyl cyclododecatriene indicates the presence of an A. terreus infection; and
the presence of one or both of 9-decene-2-one and beta-sesquiphellandrene indicates the presence of an A. calidoustus infection in the subject; and
administering a therapy comprising an azole to a subject who has an A. fumigatus infection or who has an A. terrus infection, and administering a therapy comprising amphotericin B (AMB) to a subject who has an A. calidoustus infection.
6 . The method of claim 5 ,
wherein the azole is voriconazole or the amphotericin B (AMB) is D-AMB or a lipid formulation of AMB
7 - 9 . (canceled)
10 . A method of detecting the presence of an Aspergillus fumigatus, A. terreus, or A. calidoustus infection in a culture, the method comprising:
obtaining a sample comprising gas from the headspace of the culture; determining the presence of one, two, three, or more VOCs selected from the group consisting of camphene, alpha-pinene, beta-pinene, limonene, alpha-bergamotene, alpha-santalene, beta-elemene, acoradien, chamigrene, 1,5,9-trimethyl cyclododecatriene, 9-decene-2-one and beta-sesquiphellandrene in the sample, wherein:
the presence of one, two, three, or more of camphene, alpha-pinene, beta-pinene, limonene, or alpha-bergamotene indicates the presence of A. fumigatus in the culture;
the presence of one, two, three, or more of alpha-santalene, beta-elemene, acoradien, chamigrene, and 1,5,9-trimethyl cyclododecatriene indicates the presence of A. terreus in the culture; and
the presence of one or both of 9-decene-2-one and beta-sesquiphellandrene indicates the presence of A. calidoustus infection in the culture.
11 . The method of claim 5 , wherein determining the presence of a VOC comprises assaying the sample to detect the presence the VOC.
12 . The method of claim 11 , wherein assaying the sample to detect the presence the VOC comprises using a gas chromatography (GC) or spectrometry method.
13 . The method of claim 12 , wherein the spectrophotometry method is mobility spectrometry (IMS) or differential mobility spectrometry (DMS).
14 . The method of claim 5 , wherein the subject is a human.\
15 . The method of claim 11 , wherein the subject is a human.
16 . (canceled)Join the waitlist — get patent alerts
Track US2019033290A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.